PharmaDepth

Company profile

TG THERAPEUTICS, INC.

NASDAQ:TGTXBiotechnology: Pharmaceutical Preparations

Drug pipeline (5)

AssetStageRevenueTrialsStatus
UMBRALISIB TOSYLATEapproved—0—
UMBRALISIBphase3—7completed, terminated
Cosibelimabphase1—1no active trials
EDRALBRUTINIBphase1—1terminated
Zeripatamigphase1—2completed, terminated

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (36)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT06680037phase1recruiting2025-05-062027-12-01TG Therapeutics, Inc.A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
NCT07503873phase2recruiting2026-04-012027-07-31TG Therapeutics, Inc.A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
NCT07673744phase2recruiting2026-07-302028-07-01TG Therapeutics, Inc.A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
NCT07211633phase3active_not_recruiting2025-07-092026-10-31TG Therapeutics, Inc.A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
NCT02656303phase2terminated2016-01-072022-05-26TG Therapeutics, Inc.A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304

FDA applications (2)

ApplicationTypeApplicantProducts
BLA 761238BLATG Therapeutics, Inc.
NDA 213176NDATG THERAPEUTICS INC